The problem: picking a partner that won’t derail your program
Too many programs stall because the lab hired for inhalation work, dosing accuracy, or endpoint selection can’t deliver reproducible data. You need a partner who understands respiratory biology and the mechanics of preclinical inhalation work, not just a vendor that runs routine rodent assays. Start by narrowing to a qualified respiratory CRO that demonstrates hands-on experience with inhalation exposures, pulmonary function measures, and endpoint validations relevant to COPD.
Evidence that matters: experience, verifiable methods, and a clear record
Look for specific, verifiable experience: GLP-capable inhalation rigs, validated bronchoalveolar lavage protocols, power calculations tied to primary endpoints, and pathologist-led histology readouts. Myriad studies discussed at the American Thoracic Society (ATS) International Conference highlight how model selection and exposure control change outcomes, which is why you must confirm a lab’s specific COPD model experience. If you need a direct reference for animal work, inspect their track record with the COPD animal model and ask for study-level details: inhalation concentration curves, aerosol characterization, and validation cohorts.
Concrete criteria to evaluate — no fluff
Demand these items and verify them: written SOPs for inhalation systems; reports showing aerosol particle size distribution; PK/PD sampling plans; blinded histopathology and scoring methods; specimen chain-of-custody and data audit trails; and a named pathology reviewer with publications. Ask for three recent study summaries with raw data access and contactable references. If a lab hesitates or replaces specifics with marketing language, move on.
Common mistakes teams make
Teams often accept vague assurances about “experience” without seeing method validation. They skip pilot studies that reveal exposure variability. They assume rodent endpoints translate directly to human COPD pathology. They underestimate the value of early statistical consultation, then chase underpowered endpoints. Correct these by requiring pilot validation, defining primary/secondary endpoints up front, and locking the statistical analysis plan before dosing begins.
When to go in-house vs. outsource
Keep work in-house if you must protect proprietary inhalation hardware or custom exposure chambers and you have trained staff plus GLP infrastructure. Outsource when you need rapid scale, validated COPD models, and regulated study packages for IND-enabling work. If timelines and reproducibility matter most, choose a lab with demonstrable inhalation expertise rather than a generalist that promises a quick turnaround.
Making the final decision
Send a practical request: a short technical questionnaire focused on inhalation characterization, COPD-relevant endpoints, pathology review, data access, and regulatory compliance. Score responses objectively. Visit facilities where possible. A partner that shares methods, provides pilot data, and assigns named senior scientists shows real accountability. When the program’s survival depends on clean, translatable preclinical data, the right partner mitigates risk and keeps your milestones realistic — a role that KCI Biotech can fill through experienced teams, validated COPD models, and transparent study practices.